A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development

[1]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[2]  Stefan Willmann,et al.  Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide , 2012, Molecular Diagnosis & Therapy.

[3]  Nina Jeliazkova,et al.  Web tools for predictive toxicology model building , 2012, Expert opinion on drug metabolism & toxicology.

[4]  L. Kuepfer,et al.  Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.

[5]  Stefan Willmann,et al.  Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. , 2012, Molecular diagnosis & therapy.

[6]  Yasushi Okuno,et al.  Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System , 2011, PloS one.

[7]  Y. Okuno,et al.  Data Mining of the Public Version of the FDA Adverse Event Reporting System , 2011, International journal of medical sciences.

[8]  S. Szeinbach,et al.  Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 , 2011, Pharmacoepidemiology and drug safety.

[9]  C. G. Mohan.  Impact of computational structure-based predictive toxicology in drug discovery. , 2011, Combinatorial chemistry & high throughput screening.

[10]  J. Arrowsmith.  Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.

[11]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[12]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[13]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[14]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[15]  Yiannis S. Chatzizisis,et al.  Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy , 2010, Drug safety.

[16]  M. Niemi.  Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.

[17]  Luis G Valerio,et al.  In silico toxicology for the pharmaceutical sciences. , 2009, Toxicology and applied pharmacology.

[18]  P. Moriarty,et al.  Does Simvastatin Cause More Myotoxicity Compared with Other Statins? , 2009, The Annals of pharmacotherapy.

[19]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[20]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[21]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[22]  Amy D. Kyle,et al.  Meeting Report: Moving Upstream—Evaluating Adverse Upstream End Points for Improved Risk Assessment and Decision-Making , 2008, Environmental health perspectives.

[23]  Ikumi Chisaki,et al.  Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. , 2008, Life sciences.

[24]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[25]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[26]  J. Stelling,et al.  Ensemble modeling for analysis of cell signaling dynamics , 2007, Nature Biotechnology.

[27]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[28]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[29]  M. Niemi,et al.  Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.

[30]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[31]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[32]  P. Neuvonen,et al.  Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. , 2006 .

[33]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[34]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[35]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[36]  Michael D. Waters,et al.  Toxicogenomics and systems toxicology: aims and prospects , 2004, Nature Reviews Genetics.

[37]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[38]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[39]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[40]  A. Sánchez Navarro,et al.  Clinical pharmacokinetics of statins. , 2003, Methods and findings in experimental and clinical pharmacology.

[41]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[42]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[43]  R. Pardi,et al.  Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein1 , 2000, The Journal of Immunology.

[44]  J. Nedelman,et al.  Physiologically based pharmacokinetic modeling as a tool for drug development , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[45]  Y. Nagahama,et al.  Involvement of an inhibitory G-protein in the signal transduction pathway of maturation-inducing hormone (17 alpha,20 beta-dihydroxy-4-pregnen-3-one) action in rainbow trout (Oncorhynchus mykiss) oocytes. , 1994, Developmental biology.

[46]  Ryosei Kawai,et al.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[47]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[48]  K. Goa,et al.  Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. , 1990, Drugs.

[49]  S. Singhvi,et al.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.

[50]  K. Bischoff,et al.  Generalized solution to linear, to-compartment, open model for drug distribution. , 1970, Journal of theoretical biology.

[51]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[52]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .